The Cat Practice utilizes the Merial™ PUREVAX® Feline Rabies vaccine in cats 12 weeks of age or older.

PUREVAX® Feline Rabies contains a nonadjuvanted lyophilized suspension of a recombinant vectored rabies vaccine plus a sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to rabies. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge studies in susceptible cats.

PUREVAX® Feline Rabies vaccine does not contain adjuvants, as all other rabies vaccines do. Adjuvants are substances added to a killed vaccine to increase the body’s immune response to the vaccine (since the virus is killed and doesn’t stimulate an adequate response on its own), and have been linked to vaccine-related fibrosarcomas in cats (i.e. cancerous tumors at the site of the vaccine). Although this is rare (about 1 in 10,000 cats), it is a major concern of veterinarians since this type cancer is extremely malignant, fast-growing, and will spread quickly to other parts of the body.

Therefore, The Cat Practice utilizes the safest adjuvant-free rabies vaccine possible to keep cats safe. Rabies is a human health concern, therefore all cats (as long as they are deemed healthy by a veterinarian) should be vaccinated yearly.

PUREVAX® Feline Rabies is recommended for the vaccination of healthy cats 8 weeks of age or older for prevention of disease due to rabies virus. An injection of 1 mL (1 dose) is administered subcutaneously into healthy cats. Revaccinate annually with a single 1 mL dose.

In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.

©2005 - 2008, The Cat Practice, PC. All Rights Reserved | The Cat Practice, 875 South Worth, Birmingham, MI 48009 | 248-540-3390 | info@thecatpracticepc.com